This weekend marks the start of the annual meeting of the world’s biggest gathering of cancer doctors, and it’s going to be a big one for Roger Perlmutter, the head of research and development at Merck.

Keytruda, the company’s cancer immunotherapy, is expected to reach annual sales of $10 billion by the end of its fifth year, making it the best drug launch in history over that time period, according to the investment bank Jefferies. But Perlmutter is gushing about the effects the drug has had on survival over that same time frame. New data on that metric will be presented at the upcoming meeting of the American Society of Clinical Oncology.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy